Patents Assigned to Immunotech
-
Patent number: 11813279Abstract: One aspect of this disclosure is directed to a method for treating a cancer in a subject in need thereof by administering to the subject at least a first compound and a second compound together or separately. The first compound is an effective amount of a checkpoint inhibitor optionally with at least one pharmaceutically acceptable carrier. The second compound is an effective amount of an Anti-Tumor Immune Enhancer (ATIE) optionally with at least one pharmaceutically acceptable carrier. The compounds can be administered together or separately.Type: GrantFiled: August 9, 2019Date of Patent: November 14, 2023Assignee: AIM ImmunoTech Inc.Inventors: David R. Strayer, Thomas K. Equels
-
Patent number: 11813281Abstract: The present invention relates to methods for treating a subject with myalgic encephalomyelitis/chronic fatigue syndrome symptoms comprising administering a target subject a pharmaceutical composition comprising a therapeutic dsRNA (tdsRNA).Type: GrantFiled: November 25, 2019Date of Patent: November 14, 2023Assignee: AIM ImmunoTech Inc.Inventors: David R. Strayer, Diane L. Young, Thomas K. Equels
-
Patent number: 11642396Abstract: This disclosures relates to methods of preventing or reducing antigenic drift, viral reassortment and symptoms of wild-type and mutant influenza viruses in a host animal by determining if a host animal has been exposed to or infected by an avian influenza virus, and administering to the exposed host animal ?-interferon.Type: GrantFiled: August 21, 2014Date of Patent: May 9, 2023Assignee: AIM ImmunoTech Inc.Inventors: William A. Carter, David R. Strayer
-
Publication number: 20220387475Abstract: Disclosed is a method for treating endometriosis, preventing endometriosis, or ameliorating a symptom of endometriosis in a subject comprising the step of administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising as an active ingredient a therapeutic dsRNA (tdsRNA).Type: ApplicationFiled: October 22, 2020Publication date: December 8, 2022Applicant: AIM ImmunoTech Inc.Inventors: Thomas K. EQUELS, David R. STRAYER
-
Publication number: 20220389050Abstract: Disclosed is a method for the synthesis of a therapeutic double-stranded RNA (tdsRNA), comprising: a) synthesizing a first single-stranded RNA (first ssRNA) in a first synthesis reaction with PNPase as the only RNA polymerase; b) synthesizing a second single-stranded RNA (second ssRNA) in a second synthesis reaction with PNPase as the only RNA polymerase; and c) hybridizing the first ssRNA with the second ssRNA to form the tdsRNA; wherein step a) and step b) are performed in any order. Also disclosed is a product produced by the method.Type: ApplicationFiled: January 25, 2021Publication date: December 8, 2022Applicant: AIM ImmunoTech Inc.Inventors: Thomas K. EQUELS, Vishwajeetsinh M. ATODARIA, Victoria G. SCOTT, David R. STRAYER, Peter W. RODINO
-
Publication number: 20220387472Abstract: Disclosed is a method for treating a cancer, such as pancreatic cancer, in a subject. The method comprises a first step of administering to the subject a standard of care therapy such as FOLFIRINOX and administering to the subject a therapeutic double stranded RNA (tdsRNA) which can be Rintatolimod.Type: ApplicationFiled: September 21, 2021Publication date: December 8, 2022Applicant: AIM ImmunoTech Inc.Inventors: Thomas K. EQUELS, David R. STRAYER
-
Publication number: 20220380769Abstract: This disclosure relates to a method of treating, preventing, or reducing a symptom of a virus infection, including a SARS-CoV-2 infection, by administering an effective amount of tdsRNA optionally with an anti-viral agent, to a subject.Type: ApplicationFiled: January 25, 2021Publication date: December 1, 2022Applicant: AIM ImmunoTech Inc.Inventors: Thomas K. EQUELS, David R. STRAYER, Diane L. YOUNG
-
Publication number: 20220356476Abstract: Disclosed are methods and compositions for at least preventing, treating, inhibiting, or attenuating an Ebola virus infection of a subject. The methods comprise administering an effective amount of a composition as described herein to the subject thereby at least preventing, treating, inhibiting, or attenuating the Ebola virus infection of the subject. The compositions comprise a therapeutic double-stranded RNA (tdsRNA) and additional optional components such as an Ebola antigen.Type: ApplicationFiled: July 2, 2020Publication date: November 10, 2022Applicant: AIM ImmunoTech Inc.Inventors: David R. STRAYER, Thomas K. EQUELS
-
Patent number: 11484567Abstract: The present invention concerns uses of immune suppressive domains. In particular, the present invention concerns a use of an immune suppressive domain (ISD) for immune suppression and for reduction of inflammation.Type: GrantFiled: April 10, 2014Date of Patent: November 1, 2022Assignees: Aarhus Universitet, iSD Immunotech ApSInventors: Shervin Bahrami, Mogens Ryttergård Duch, Christian Kanstrup Holm, Magdalena Janina Laska
-
Publication number: 20220280547Abstract: This disclosure relates to compositions and methods for treating a subject previously infected with a virus and afflicted with post viral fatigue symptoms such as, for example, Long Covid. The compositions and methods comprise a therapeutically effective amount of a composition comprising therapeutic double-stranded RNA tdsRNA.Type: ApplicationFiled: May 16, 2022Publication date: September 8, 2022Applicant: AIM ImmunoTech Inc.Inventors: Thomas K. EQUELS, David R. STRAYER, Diane L. YOUNG
-
Publication number: 20220096518Abstract: One aspect of this disclosure is directed to a method for treating a cancer in a subject in need thereof by administering to the subject at least a first compound and a second compound in any order together or separately. The first compound is an effective amount of a checkpoint inhibitor optionally with at least one pharmaceutically acceptable carrier. The second compound is an effective amount of an Therapeutic Double Stranded RNA (tdsRNA) optionally with at least one pharmaceutically acceptable carrier. The compounds can be administered together or separately. Compositions for the practice of the method are also described.Type: ApplicationFiled: December 20, 2019Publication date: March 31, 2022Applicant: AIM ImmunoTech Inc.Inventors: David R. STRAYER, Thomas K. EQUELS
-
Publication number: 20220062321Abstract: The present invention relates to methods for treating a subject with myalgic encephalomyelitis/chronic fatigue syndrome symptoms comprising administering a target subject a pharmaceutical composition comprising a therapeutic dsRNA (tdsRNA).Type: ApplicationFiled: November 25, 2019Publication date: March 3, 2022Applicant: AIM ImmunoTech Inc.Inventors: David R. STRAYER, Diane L. YOUNG, Thomas K. EQUELS
-
Publication number: 20210196744Abstract: One aspect of this disclosure is directed to a method for treating a cancer in a subject in need thereof by administering to the subject at least a first compound and a second compound together or separately. The first compound is an effective amount of a checkpoint inhibitor optionally with at least one pharmaceutically acceptable carrier. The second compound is an effective amount of an Anti-Tumor Immune Enhancer (ATIE) optionally with at least one pharmaceutically acceptable carrier. The compounds can be administered together or separately.Type: ApplicationFiled: February 18, 2021Publication date: July 1, 2021Applicant: AIM ImmunoTech Inc.Inventors: David R. STRAYER, Thomas K. EQUELS
-
Patent number: 10961279Abstract: The present invention relates to enveloped RNA viruses. The invention in particular relates to the generation of superior antigens for mounting an immune response by first identifying then mutating the immunosuppressive domains in fusion proteins of enveloped RNA viruses resulting in decreased immunosuppressive properties of viral envelope proteins from the viruses.Type: GrantFiled: June 10, 2016Date of Patent: March 30, 2021Assignee: ISD Immunotech ApSInventors: Mogens Ryttergaard Duch, Shervin Bahrami
-
Publication number: 20200197433Abstract: One aspect of this disclosure is directed to a method for treating a cancer in a subject in need thereof by administering to the subject at least a first compound and a second compound together or separately. The first compound is an effective amount of a checkpoint inhibitor optionally with at least one pharmaceutically acceptable carrier. The second compound is an effective amount of an Anti-Tumor Immune Enhancer (ATIE) optionally with at least one pharmaceutically acceptable carrier. The compounds can be administered together or separately.Type: ApplicationFiled: August 9, 2019Publication date: June 25, 2020Applicant: AIM IMMUNOTECH INC.Inventors: David R. STRAYER, Thomas K. EQUELS
-
Patent number: 7678583Abstract: A multifunctional reagent for erythrocytes containing an amount sufficient to produce the lysis of erythrocytes or the sphering of erythrocytes in such a way that they can be detected by a cytometer or an automatic counting device, of a carbamate or of an agent inducing the formation by the erythrocytes, from carbonate and from a nitrogenated heterocycle or ammonium ions, of a carbamate combined with the absorption of CO2 by the erythrocytes, process for lysing or sphering erythrocytes and preparation process for leucocytes.Type: GrantFiled: October 8, 2007Date of Patent: March 16, 2010Assignee: Immunotech, S.A.Inventors: Andre van Agthoven, Jean-Pierre Daziano, John Allen Maples
-
Publication number: 20090117667Abstract: The present invention provides methods for measuring an affinity substance using pearl chain formation of carrier particles, in which the methods include the step of electrically disrupting blood cell components. Blood cell components which interfere with the counting of carrier particles are electrically disrupted. Furthermore, blood cell components can be disrupted without addition of hemolytic agents which interfere with immunological reactions. Whole blood samples can be directly used as measurement samples without separating serum or plasma. Therefore, it is unnecessary to separate serum or plasma when analyzing blood components.Type: ApplicationFiled: September 29, 2006Publication date: May 7, 2009Applicant: PULSE-IMMUNOTECH CORPORATIONInventor: Keisuke Iwata
-
Publication number: 20090060937Abstract: Oligonucleotides containing the non-palindromic sequence motif: X1X2X3X4X5X6X7X8, wherein X1 is C, T, G or A (preferably T or C); wherein X2 is C, T, G or A; wherein X7 is C, T, G or A (preferably G); at least three, and preferably all, of X3, X4, X5, X6 and X8 are T; and with the proviso that, in the motif, a C does not precede a G (in other terms, the nucleic acid motif does not consist of a CpG oligonucleotide), that modulate the immune response of animals of the order Primate, including humans, are disclosed. This immune modulation is characterized by stimulation of proliferation, differentiation, cytokine production and antibody production on B-cells and cell differentiation on plasmacytoid dendritic cells.Type: ApplicationFiled: April 28, 2008Publication date: March 5, 2009Applicant: IMMUNOTECH S.A.Inventor: Ricardo Agustin Lopez
-
Patent number: 7381807Abstract: Oligonucleotides containing the non-palindromic sequence motif: X1X2X3X4X5X6X7X8, wherein X1 is C,T,G or A (preferably T or C); wherein X2 is C,T,G or A; wherein X7 is C,T,G or A (preferably G); at least three, and preferably all, of X3, X4, X5, X6 and X8 are T; and with the proviso that, in the motif, a C does not precede a G (in other terms, the nucleic acid motif does not consist of a CpG oligonucleotide), that modulate the immune response of animals of the order Primate, including humans, are disclosed. This immune modulation is characterized by stimulation of proliferation, differentiation, cytokine production and antibody production on B-cells and cell differentiation on plasmacytoid dendritic cells.Type: GrantFiled: July 8, 2005Date of Patent: June 3, 2008Assignee: Immunotech S.A.Inventor: Ricardo Agustin Lopez
-
Patent number: 7300797Abstract: A multifunctional reagent for erythrocytes containing an amount sufficient to produce the lysis of erythrocytes or the sphering of erythrocytes in such a way that they can be detected by a cytometer or an automatic counting device, of a carbamate or of an agent inducing the formation by the erythrocytes, from carbonate and from a nitrogenated heterocycle or ammonium ions, of a carbamate combined with the absorption of CO2 by said erythrocytes, process for lysing or sphering erythrocytes and preparation process for leucocytes.Type: GrantFiled: September 14, 2001Date of Patent: November 27, 2007Assignee: Immunotech, S.A.Inventors: Andre van Agthoven, Jean-Pierre Daziano, John Allen Maples